Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Second-quarter fiscal 2010 results announced by Repligen

Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.

5 Nov 2009

NIST researchers to develop a certified reference material to assess C-reactive protein

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood).

5 Nov 2009

Phadia offers ImmunoCAP, a reliable test to accurately diagnose the severity of egg allergy

The World Health Organization recently declared H1N1 swine flu a global pandemic, resulting in the creation of rigorous vaccination programs worldwide. Children are among those considered particularly susceptible to contracting swine flu and are viewed as a top priority in receiving this vaccine.

5 Nov 2009

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Study on asbestos-related diseases in Libby launched

Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List."

4 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

New strategy to eliminate and eradicate malaria unveiled

Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria

4 Nov 2009

Common pain killers may blunt the effect of flu shots

With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.

4 Nov 2009

Symphogen announces the opening of its United States headquarters in Princeton

Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 7,597,895 entitled "Signal peptides, nucleic acid molecules and methods for treatment of caries" by the U.S. Patent and Trademark Office. This is the third patent to issue protecting Kane Biotech's CSP (Competence Stimulating Peptide) technology.

3 Nov 2009

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has exercised its option to purchase $12.8 million of additional convertible preferred stock under the terms described in the financing agreements approved by GTC shareholders in July 2009. This transaction provides $6.4 million of new cash proceeds to GTC.

2 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

Antibody News and Research

Further Reading

Second-quarter fiscal 2010 results announced by Repligen

NIST researchers to develop a certified reference material to assess C-reactive protein

Phadia offers ImmunoCAP, a reliable test to accurately diagnose the severity of egg allergy

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Study on asbestos-related diseases in Libby launched

ThromboGenics issues business update for the third-quarter of 2009

New strategy to eliminate and eradicate malaria unveiled

Common pain killers may blunt the effect of flu shots

Symphogen announces the opening of its United States headquarters in Princeton

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

Mechanical force switches T cell from disease-scanning to disease-fighting mode

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News